Treatment of different cancers

Two clinical studies

  • Skin Papilloma
  • Bladder Cancer

Three animal models

  • Brain Tumours, glioblastoma
  • Bladder Carcinoma
  • Colon / Intestinal Cancer

The new drug candidate α1H

  • Bladder Cancer in mice

Next step

  • Clinical bladder cancer trial

click map

Treatment of Skin Papillomas with Topical a-Lactalbumin–Oleic Acid Human -Lactalbumin Made Lethal to Tumor Cells (HAMLET) Kills Human Glioblastoma Cells in Brain Xenografts by an Apoptosis-Like Mechanism and Prolongs Survival Bladder cancers respond to intravesical instillation of HAMLET (human a-lactalbumin made lethal to tumor cells) HAMLET Treatment Delays Bladder Cancer Development Prevention and treatment of colon cancer by peroral administration of HAMLET (human α-lactalbumin made lethal to tumour cells)

Towards the clinical trial of α1H in patients with bladder cancer

Achievements of HAMLET Pharma since Nov.2015

Hamlet Pharma, Interview

Life Science Day 2017 (SWE)

A new concept for cancer therapy

HAMLET is a tumor killing protein-lipid complex, formed by two naturally occurring molecules from human milk. HAMLET is an abbreviation for Human Alpha-lactalbumin Made LEthal to Tumor Cells. α1H is a peptide that includes key tumoricidal motifs within HAMLET. Together with oleic acid, α1H forms a complex that target cancer tissues selectively similar to HAMLET. HAMLET Pharma develops novel cancer therapeutic based on the HAMLET molecule and more recently on α1H.

Read more about HAMLET >>